Answers are grounded in this paper and cite their sources.
Retrospective study examines chemotherapy's limited efficacy and significant risks in unresectable ganglioneuroblastoma intermixed, suggesting surgery is a better option.
Ganglioneuroblastoma intermixed (GNB-I) is a rare pediatric tumor with favorable outcomes when treated primarily with surgical resection. In patients for whom surgical intervention is not feasible, chemotherapy is often considered, although its efficacy remains controversial. This retrospective study examined 12 patients with nonmetastatic GNB-I at Phoenix Children’s Hospital. Four patients received chemotherapy but showed no significant tumor reduction postchemotherapy, and all required surgery afterward. Chemotherapy led to notable toxicities, including febrile neutropenia and anaphylactic reaction. These findings suggest chemotherapy offers limited benefit while posing significant risks of cytotoxic adverse events for unresectable GNB-I, and surgery should be prioritized. Further longitudinal studies are needed to confirm these results.
No takes yet. Share an insight, caveat, or question.
Nourani et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: